Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Oct 18 - Oct 23
Traditionally, GLP-1 receptor agonists like semaglutide and liraglutide have been used to manage type 2 diabetes and obesity due to their ability to promote satiety and lower blood sugar levels
Key findings: Semaglutide has been linked to higher odds of depression (1.87x) and suicidal behavior (1.73x) in some reports, though clinical trials show no consistent increase in psychiatric risks
In addition, SGLT-2 inhibitors have shown benefit in patients with both HFrEF and HFpEF independently of diabetes status, which opens exciting possibilities for the use of these therapies in patients at risk for or with established CV or kidney disease without T2D
Food and Drug Administration (FDA) on the 1st approved 'Foundayo (ingredient name: orforglipron),' an oral obesity treatment developed by Eli Lilly, the company that supplies the obesity drug 'Mounjaro.' This is the second oral GLP-1 class obesity treatment to be approved, following the pill form of Novo Nordisk's 'Wegovy' last December
Nat Rev Dis Primers (2016) 2:16065
US$ 26.51
US$ 23.44
US$ 26.65
US$ 28.35
US$ 28.67
US$ 28.96
